| Submit your comments on this article |
| Economy |
| Goldman Sachs Analysts Question Whether Curing Patients Is Good for Business |
| 2018-04-17 |
| h/t Instapundit [Gizmodo] Recent advancements in science and medicine have put cures within reach for diseases that have long plagued humankind. In a recent report, though, Goldman Sachs analysts posed an uncomfortable question that quickly sparked criticism. "Is curing patients a sustainable business model?" analysts asked in an April 10 report entitled "The Genome Revolution," which CNBC first reported. One-and-done cures enabled by gene editing, analyst Salveen Richter wrote in the note to clients this week, are near-miraculous innovations that stand to benefit patients immensely. But they also present a challenge to business. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow," she wrote. |
| Posted by:g(r)omgoru |
| #3 Except it shows you what's wrong with "Economics", Darth |
| Posted by: g(r)omgoru 2018-04-17 11:15 |
| #2 There will always be a need for genome fixing and cancer cures as there will always be issues. So a one and done doesn't mean you develop and never use again. There will be another baby along the way that has issues. |
| Posted by: DarthVader 2018-04-17 10:54 |
| #1 Rhetorical question of course. |
| Posted by: Besoeker 2018-04-17 10:51 |